Duncan Hewett

Dr. Duncan Hewett is a Grant-Funded Researcher B at the University of Adelaide’s School of Biomedicine under the Faculty of Health and Medical Sciences. He is affiliated with the Precision Cancer Medicine Theme at SAHMRI (South Australian Health and Medical Research Institute) on North Terrace. His work focuses on multiple myeloma, investigating mechanisms of disease progression and evaluating novel therapeutics. Key projects include CRISPR-Cas9 genetic screens to identify survival mechanisms in the bone marrow microenvironment and optimizing lenalidomide-responsive mouse models to discover drug synergies.

• Affiliations: University of Adelaide, SAHMRI, Myeloma Research Group (led by Dr. Kate Vandyke)
• Location: SAHMRI, Level 5 South, North Terrace, Adelaide

Research interests center on hematological malignancies, particularly the role of dysregulated genes and the tumor microenvironment. Dr. Hewett’s methodologies include cell-based and murine models to study myeloma pathogenesis and therapeutic efficacy. He is actively supervising Honours and HDR students for projects starting in 2025, focusing on experimental therapeutics and genomic approaches.

His publications span mechanisms of myeloma dissemination, genetic drivers (e.g., CCR1, Samsn1, Gremlin1), and therapeutic strategies targeting enzymes like myeloperoxidase. Though no awards are explicitly listed, his contributions to understanding myeloma biology reflect a commitment to advancing precision medicine in oncology.

Laboratory: Precision Cancer Medicine Theme at SAHMRI, collaborating on preclinical drug development and genomic screening.